2-氯-5,6-二甲氧基嘧啶-4-羧酸甲酯 | 923938-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氯-5,6-二甲氧基嘧啶-4-羧酸甲酯
• 英文名称: methyl 2-chloro-5,6-dimethoxypyrimidine-4-carboxylate
• CAS: 923938-13-0
• 化学式: C₈H₉ClN₂O₄
• 分子量: 232.623
• InChiKey: VHMJXXGDXNEVFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  70.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-氯-5,6-二甲氧基嘧啶-4-羧酸甲酯 在 双氧水 、 三溴化硼 、 溶剂黄146 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 为溶剂， 反应 36.0h， 生成 5,6-Dihydroxy-2-methanesulfonyl-pyrimidine-4-carboxylic acid
  参考文献：
  名称：

  2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as Inhibitors of the Hepatitis C Virus NS5B Polymerase:  Discovery, SAR, Modeling, and Mutagenesis

  摘要：

  Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The polymerase of HCV is responsible for the replication of viral RNA. We recently disclosed dihydroxypyrimidine carboxylates 2 as novel, reversible inhibitors of the HCV NS5B polymerase. This series was further developed into 5,6-dihydroxy-2-(2-thienyl)pyrimidine-4-carboxylic acids such as 34 (EC50 9.3 mu M), which now show activity in the cell-based HCV replication assay. The structure-activity relationship of these inhibitors is discussed in the context of their physicochemical properties and of the polymerase crystal structure. We also report the results of mutagenesis experiments which support the proposed binding model, which involves pyrophosphate-like chelation of the active site Mg ions.

  DOI：

  10.1021/jm051064t
• 作为产物：
  描述：

  methyl 2,6-dihydroxy-5-methoxypyrimidine-4-carboxylate 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 0.5h， 生成 2-氯-5,6-二甲氧基嘧啶-4-羧酸甲酯
  参考文献：
  名称：

  2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as Inhibitors of the Hepatitis C Virus NS5B Polymerase:  Discovery, SAR, Modeling, and Mutagenesis

  摘要：

  Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The polymerase of HCV is responsible for the replication of viral RNA. We recently disclosed dihydroxypyrimidine carboxylates 2 as novel, reversible inhibitors of the HCV NS5B polymerase. This series was further developed into 5,6-dihydroxy-2-(2-thienyl)pyrimidine-4-carboxylic acids such as 34 (EC50 9.3 mu M), which now show activity in the cell-based HCV replication assay. The structure-activity relationship of these inhibitors is discussed in the context of their physicochemical properties and of the polymerase crystal structure. We also report the results of mutagenesis experiments which support the proposed binding model, which involves pyrophosphate-like chelation of the active site Mg ions.

  DOI：

  10.1021/jm051064t

文献信息

• [EN] INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS<br/>[FR] INHIBITEURS DE CATÉCHOL O-MÉTHYL TRANSFÉRASE ET UTILISATION ASSOCIÉE DANS LE TRAITEMENT DE TROUBLES PSYCHOTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2011109267A1

  公开（公告）日：2011-09-09

  The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

  本发明涉及4-吡啶酮化合物，它们是儿茶酚-O-甲基转移酶(COMT)的抑制剂，并且在治疗和预防涉及COMT酶的神经和精神障碍和疾病方面具有用处。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及COMT的这类疾病中使用这些化合物和组合物。
• INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS
  申请人：Wolkenberg Scott

  公开号：US20130196002A1

  公开（公告）日：2013-08-01

  The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

  本发明涉及4-吡啶酮类化合物，它们是儿茶酚-O-甲基转移酶(COMT)的抑制剂，可用于治疗和预防涉及COMT酶的神经和精神障碍和疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及COMT的这些疾病中使用这些化合物和组合物。
• US8969364B2
  申请人：——

  公开号：US8969364B2

  公开（公告）日：2015-03-03
• US9260413B2
  申请人：——

  公开号：US9260413B2

  公开（公告）日：2016-02-16
• 2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as Inhibitors of the Hepatitis C Virus NS5B Polymerase:  Discovery, SAR, Modeling, and Mutagenesis
  作者：Uwe Koch、Barbara Attenni、Savina Malancona、Stefania Colarusso、Immacolata Conte、Marcello Di Filippo、Steven Harper、Barbara Pacini、Claudia Giomini、Steven Thomas、Ilario Incitti、Licia Tomei、Raffaele De Francesco、Sergio Altamura、Victor G. Matassa、Frank Narjes

  DOI：10.1021/jm051064t

  日期：2006.3.1

  Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The polymerase of HCV is responsible for the replication of viral RNA. We recently disclosed dihydroxypyrimidine carboxylates 2 as novel, reversible inhibitors of the HCV NS5B polymerase. This series was further developed into 5,6-dihydroxy-2-(2-thienyl)pyrimidine-4-carboxylic acids such as 34 (EC50 9.3 mu M), which now show activity in the cell-based HCV replication assay. The structure-activity relationship of these inhibitors is discussed in the context of their physicochemical properties and of the polymerase crystal structure. We also report the results of mutagenesis experiments which support the proposed binding model, which involves pyrophosphate-like chelation of the active site Mg ions.